Furthermore, a subanalysis of the ACCOMPLISH trial found that patients with obesity taking a combination of ACE inhibitors and diuretics were 39%, 60%, and 40% less likely to experience primary CVD morbidity outcomes, CVD deaths, and total stroke, respectively, when compared to normal weight individuals taking the same medications. This evidence concerns the gene ACE and Stroke.